NCT02279667View on ClinicalTrials.gov

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

Epilepsy

Interventions

DRUG

BIA 2-093

oral suspension 50 mg/mL

DRUG

BIA 2-093

200 mg tablet

DRUG

BIA 2-093

800 mg tablet

Trial Locations (1)

Unknown

CEB - Centre for Bioavailability Studies, AIBILI, Azinhaga de Santa Comba - Celas

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT02279667 - Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 | Biotech Hunter | Biotech Hunter